RxDoctor Payments Data

Brett Ferrell, MD

Family Medicine · Tullahoma, TNNPI 1356646434

Payments from drug & device makers

$11,367in general payments, 2019–2025

Across 779 payments — averaging $14.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$833
  • Amgen$829
  • Lilly USA, LLC$745
  • Pfizer$636
  • AbbVie$605
  • plus $6K from 53 others

What the payments were for

  • Food & beverage$11,367100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk184$1,824
AstraZeneca35$833
Amgen51$829
Lilly USA, LLC54$745
Pfizer48$636
AbbVie(2 entities)41$605
Boehringer Ingelheim31$531
Novartis28$437
Esperion Therapeutics, Inc.25$375
Merck32$340
Otsuka America Pharmaceutical, Inc.14$276
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC15$267
Astellas Pharma US Inc17$257
Johnson & Johnson17$248
Bayer11$236
GSK15$213
Antares Pharma, Inc.13$210
Xeris Pharmaceuticals, Inc.10$198
Takeda Pharmaceuticals U.S.A., Inc.10$169
Biohaven Pharmaceuticals, Inc.10$153
Dexcom, Inc.8$149
Daiichi Sankyo Inc.7$128
Teva Pharmaceuticals USA, Inc.8$121
E.r. Squibb & Sons, L.L.C.8$119
Grifols USA, LLC6$114
Amarin Pharma, Inc.7$103
Eisai Inc.6$92
Supernus Pharmaceuticals, Inc.5$82
Sanofi-aventis U.S. LLC5$74
Exact Sciences4$65
Avanir Pharmaceuticals, Inc.4$63
Seqirus USA Inc3$62
Biohaven Pharmaceutical Holding Company Ltd.3$61
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$61
Lundbeck LLC3$54
Paratek Pharmaceuticals, Inc.3$52
Sumitomo Pharma America, Inc.4$50
Qorumpartners2$44
Mylan Specialty L.p.3$44
Sanofi Pasteur Inc.2$42
Medtronic(2 entities)2$41
Radius Health, Inc.2$36
Verity Pharmaceuticals Inc.2$36
Insulet Corporation2$32
Genentech USA, Inc.2$32
Verona Pharma, Inc.1$29
Valeritas, Inc.1$23
Clarus Therapeutics Inc.1$21
Shield Therapeutics Inc1$19
SK Life Science, Inc.1$19
Tolmar, Inc.1$16
Nalpropion Pharmaceuticals LLC1$15
Jazz Pharmaceuticals Inc.1$14
Idorsia Pharmaceuticals US Inc1$14
Nestle Healthcare Nutrition Inc.1$13
Corcept Therapeutics1$13
Ironwood Pharmaceuticals, Inc1$13
Sun Pharmaceutical Industries Inc.1$12
Biogen1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,367 in reported general payments places this provider in the 90th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$212,944
Medicare patients
422
Services billed
5,183

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban379$171,900
OzempicSemaglutide114$144,313
TrulicityDulaglutide98$66,733
XareltoRivaroxaban70$54,310
BiktarvyBictegrav/Emtricit/Tenofov Ala12$50,482
FarxigaDapagliflozin Propanediol86$48,284
JanuviaSitagliptin Phosphate60$41,803
JardianceEmpagliflozin48$38,564
Breztri AerosphereBudesonide/Glycopyr/Formoterol33$20,815
Tresiba Flextouch U-200Insulin Degludec28$20,705
EntrestoSacubitril/Valsartan45$20,387
Breo ElliptaFluticasone/Vilanterol40$18,411
Darunavir13$17,408
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$17,085
MyrbetriqMirabegron44$14,579

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$636$185,357393 claims
Novo NordiskOzempic$1,824$144,313114 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$833$75,102138 claims
Lilly USA, LLCTrulicity$745$66,73398 claims
Johnson & JohnsonXarelto$248$54,31070 claims
MerckJanuvia$340$41,80360 claims
Boehringer IngelheimJardiance$531$38,56448 claims
GSKBreo Ellipta, Trelegy Ellipta$213$35,49763 claims
NovartisEntresto$437$20,38745 claims
AbbVieLinzess, Namzaric$605$18,66836 claims
Astellas Pharma US IncMyrbetriq$257$14,57944 claims
Avanir Pharmaceuticals, Inc.Nuedexta$63$12,66814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Tullahoma

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →